1388-P：孕期患有 1 型糖尿病和对照的孕产妇和新生儿结局,Diabetes

当前位置： X-MOL 学术 › Diabetes › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

1388-P：孕期患有 1 型糖尿病和对照的孕产妇和新生儿结局
Diabetes ( IF 6.2 ) Pub Date : 2020-06-01 , DOI: 10.2337/db20-1388-p
RAVINDER JEET KAUR ₁ , SHAFAQ RAZA RIZVI ₁ , MARI CHARISSE TRINIDAD ₁ , BYRON H. SMITH ₁ , SREEDHAR BATTHULA ₁ , SHELLY K. MCCRADY-SPITZER ₁ , COREY REID ₁ , DONNA DESJARDINS ₁ , GRENYE O’MALLEY ₁ , KRISTIN N. CASTORINO ₁ , JORDAN E. PINSKER ₁ , WALTER K. KREMERS ₁ , EYAL DASSAU ₁ , CAROL J. LEVY ₁ , YOGISH C. KUDVA ₁

Affiliation

背景：关于美国既往 1 型糖尿病 (T1D) 妊娠结局的同期数据有限目的：确定既往 1 型糖尿病 (T1D) 妊娠与年龄、胎次和 BMI 匹配的健康受试者妊娠的母婴结局。方法：我们回顾性研究了年龄（平均 25.83 岁）、妊娠/胎次{G1P1 (66)、G2P1 (19)、G3P1 (9) 和 G4P1 (6) %} 和 BMI 相匹配的 32 例妊娠从 2015 年 1 月 1 日起在罗切斯特梅奥诊所的 5 年期间进行对照（n = 32）。结果：在 32 例 T1D 妊娠中，与对照组无先天缺陷或死亡相比，在新生儿中观察到 4 例（12.5%）先天性缺陷 (CD)，1 例肋骨发育不良伴拇指发育不良和 3 例先天性心脏缺陷导致死亡. 串联糖尿病护理。研究支持；自己; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Tandem Diabetes Care。议长局；自己; 串联糖尿病护理。WK Kremers：研究支持；自己; 阿斯利康。E. Dassau：顾问；自己; 礼来公司。研究支持；自己; Dexcom, Inc.、DreaMed Diabetes、Tandem Diabetes Care、Xeris Pharmaceuticals, Inc. 议长局；自己; 罗氏糖尿病护理。其他关系；自己; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care。CJ Levy：顾问；自己; Dexcom, Inc. 员工；配偶/伴侣; 艾尔建公司研究支持；自己; 雅培、Dexcom 公司、Insulet 公司。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。美敦力，串联糖尿病护理。议长局；自己; 串联糖尿病护理。WK Kremers：研究支持；自己; 阿斯利康。E. Dassau：顾问；自己; 礼来公司。研究支持；自己; Dexcom, Inc.、DreaMed Diabetes、Tandem Diabetes Care、Xeris Pharmaceuticals, Inc. 议长局；自己; 罗氏糖尿病护理。其他关系；自己; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care。CJ Levy：顾问；自己; Dexcom, Inc. 员工；配偶/伴侣; 艾尔建公司研究支持；自己; 雅培、Dexcom 公司、Insulet 公司。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。美敦力，串联糖尿病护理。议长局；自己; 串联糖尿病护理。WK Kremers：研究支持；自己; 阿斯利康。E. Dassau：顾问；自己; 礼来公司。研究支持；自己; Dexcom, Inc.、DreaMed Diabetes、Tandem Diabetes Care、Xeris Pharmaceuticals, Inc. 议长局；自己; 罗氏糖尿病护理。其他关系；自己; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care。CJ Levy：顾问；自己; Dexcom, Inc. 员工；配偶/伴侣; 艾尔建公司研究支持；自己; 雅培、Dexcom 公司、Insulet 公司。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。研究支持；自己; Dexcom, Inc.、DreaMed Diabetes、Tandem Diabetes Care、Xeris Pharmaceuticals, Inc. 议长局；自己; 罗氏糖尿病护理。其他关系；自己; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care。CJ Levy：顾问；自己; Dexcom, Inc. 员工；配偶/伴侣; 艾尔建公司研究支持；自己; 雅培、Dexcom 公司、Insulet 公司。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。研究支持；自己; Dexcom, Inc.、DreaMed Diabetes、Tandem Diabetes Care、Xeris Pharmaceuticals, Inc. 议长局；自己; 罗氏糖尿病护理。其他关系；自己; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care。CJ Levy：顾问；自己; Dexcom, Inc. 员工；配偶/伴侣; 艾尔建公司研究支持；自己; 雅培、Dexcom 公司、Insulet 公司。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。YC Kudva：研究支持；自己; Dexcom, Inc., 罗氏糖尿病护理。其他关系；自己; 雅培。

"点击查看英文标题和摘要"

1388-P: Maternal and Neonatal Outcomes in Pregnancies with Preexisting Type 1 Diabetes and Controls

Background: There are limited contemporaneous data about outcomes in pregnancies with pre-existing type 1 diabetes (T1D) in the U.S. Objective: To determine maternal and neonatal outcomes in pregnancies with preexisting T1D and pregnancies in age, parity and BMI matched healthy subjects. Methods: We retrospectively studied 32 pregnancies in patients with preexisting T1D matched for age (mean 25.83 years), gravidity/parity {G1P1 (66), G2P1 (19), G3P1 (9) and G4P1 (6) % respectively} and BMI with controls (n=32) during a 5 year period from 01/01/2015 at Mayo Clinic, Rochester. Results: In 32 T1D pregnancies, 4 (12.5%) congenital defects (CD) were observed in neonates, 1-dysplastic ribs with thumb hypoplasia and 3-congentinal heart defects leading to death in one in comparison to no congenital defect or death in controls. CD pregnancies were complicated by severe pre-eclampsia in all 4 and poor glycemic control (HbA1c >8) in 3. There was a significant difference in Apgar score at 1 min between T1D pregnancies and controls (p= Conclusion: Pregnancies in T1D continue to be high risk pregnancies and need tight glycemic control with a more advanced system such as closed loop insulin delivery during pregnancy to improve maternal and neonatal outcomes. Disclosure R. Kaur: None. S. Rizvi: None. M. Trinidad: None. B.H. Smith: None. S. Batthula: None. S.K. McCrady-Spitzer: None. C. Reid: None. D. Desjardins: None. G. O’Malley: Research Support; Self; Abbott, Dexcom, Inc. K.N. Castorino: Research Support; Self; Abbott, Dexcom, Inc., Medtronic, Mylan, Novo Nordisk Inc. J.E. Pinsker: Advisory Panel; Self; Medtronic. Consultant; Self; Eli Lilly and Company, Tandem Diabetes Care. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Tandem Diabetes Care. Speaker’s Bureau; Self; Tandem Diabetes Care. W.K. Kremers: Research Support; Self; AstraZeneca. E. Dassau: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., DreaMed Diabetes, Tandem Diabetes Care, Xeris Pharmaceuticals, Inc. Speaker’s Bureau; Self; Roche Diabetes Care. Other Relationship; Self; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care. C.J. Levy: Consultant; Self; Dexcom, Inc. Employee; Spouse/Partner; Allergan plc. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation. Y.C. Kudva: Research Support; Self; Dexcom, Inc., Roche Diabetes Care. Other Relationship; Self; Abbott.

更新日期：2020-06-01

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南